Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of “Hold” by Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have received an average recommendation of “Hold” from the eleven research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $25.6250.

A number of research analysts have issued reports on JSPR shares. UBS Group decreased their target price on Jasper Therapeutics from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, August 15th. BTIG Research cut their price objective on Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Wednesday, October 8th. JMP Securities dropped their target price on shares of Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating on the stock in a report on Monday, September 22nd. Finally, Evercore ISI reduced their price target on shares of Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating for the company in a report on Monday, September 22nd.

Insider Activity at Jasper Therapeutics

In other news, Director Thomas G. Wiggans acquired 41,000 shares of Jasper Therapeutics stock in a transaction dated Monday, September 22nd. The stock was bought at an average cost of $2.43 per share, with a total value of $99,630.00. Following the completion of the transaction, the director directly owned 41,000 shares of the company’s stock, valued at approximately $99,630. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Judith Anne Shizuru bought 41,000 shares of the company’s stock in a transaction that occurred on Monday, September 22nd. The stock was purchased at an average cost of $2.43 per share, for a total transaction of $99,630.00. Following the transaction, the director owned 156,901 shares in the company, valued at $381,269.43. The trade was a 35.38% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 143,000 shares of company stock valued at $347,490 in the last quarter. 4.60% of the stock is currently owned by company insiders.

Institutional Trading of Jasper Therapeutics

A number of institutional investors have recently made changes to their positions in JSPR. Acadian Asset Management LLC bought a new position in Jasper Therapeutics in the first quarter valued at $46,000. Voleon Capital Management LP acquired a new position in shares of Jasper Therapeutics during the 3rd quarter worth about $50,000. Marex Group plc bought a new position in shares of Jasper Therapeutics in the 2nd quarter valued at about $74,000. Engineers Gate Manager LP acquired a new stake in shares of Jasper Therapeutics in the second quarter valued at about $78,000. Finally, Two Sigma Investments LP bought a new stake in Jasper Therapeutics during the third quarter worth about $96,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Price Performance

Shares of JSPR stock opened at $1.70 on Friday. The stock has a market cap of $47.57 million, a PE ratio of -0.29 and a beta of 2.83. The stock has a 50-day moving average of $2.23 and a 200-day moving average of $3.45. Jasper Therapeutics has a one year low of $1.56 and a one year high of $26.05.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Monday, November 10th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.12). As a group, research analysts anticipate that Jasper Therapeutics will post -4.47 earnings per share for the current year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.